1. Home
  2. CTKB vs MREO Comparison

CTKB vs MREO Comparison

Compare CTKB & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTKB
  • MREO
  • Stock Information
  • Founded
  • CTKB 1990
  • MREO 2015
  • Country
  • CTKB United States
  • MREO United Kingdom
  • Employees
  • CTKB N/A
  • MREO N/A
  • Industry
  • CTKB Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • MREO Biotechnology: Pharmaceutical Preparations
  • Sector
  • CTKB Health Care
  • MREO Health Care
  • Exchange
  • CTKB Nasdaq
  • MREO Nasdaq
  • Market Cap
  • CTKB 430.6M
  • MREO 438.8M
  • IPO Year
  • CTKB 2021
  • MREO N/A
  • Fundamental
  • Price
  • CTKB $3.69
  • MREO $1.76
  • Analyst Decision
  • CTKB Hold
  • MREO Strong Buy
  • Analyst Count
  • CTKB 4
  • MREO 5
  • Target Price
  • CTKB $6.00
  • MREO $7.20
  • AVG Volume (30 Days)
  • CTKB 960.6K
  • MREO 4.4M
  • Earning Date
  • CTKB 08-05-2025
  • MREO 08-12-2025
  • Dividend Yield
  • CTKB N/A
  • MREO N/A
  • EPS Growth
  • CTKB N/A
  • MREO N/A
  • EPS
  • CTKB N/A
  • MREO N/A
  • Revenue
  • CTKB $197,050,000.00
  • MREO N/A
  • Revenue This Year
  • CTKB $0.91
  • MREO N/A
  • Revenue Next Year
  • CTKB $7.75
  • MREO $51.92
  • P/E Ratio
  • CTKB N/A
  • MREO N/A
  • Revenue Growth
  • CTKB N/A
  • MREO N/A
  • 52 Week Low
  • CTKB $2.37
  • MREO $1.57
  • 52 Week High
  • CTKB $7.63
  • MREO $5.02
  • Technical
  • Relative Strength Index (RSI)
  • CTKB 60.88
  • MREO 35.35
  • Support Level
  • CTKB $3.20
  • MREO $1.65
  • Resistance Level
  • CTKB $3.44
  • MREO $1.89
  • Average True Range (ATR)
  • CTKB 0.18
  • MREO 0.15
  • MACD
  • CTKB 0.01
  • MREO -0.03
  • Stochastic Oscillator
  • CTKB 96.77
  • MREO 12.84

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Share on Social Networks: